Relief Therapeutics Holding SA (LON:0QKQ)
3.200
-0.030 (-0.93%)
At close: Feb 21, 2025
LON:0QKQ Revenue
Relief Therapeutics Holding had revenue of 3.01M CHF in the half year ending December 31, 2023, a decrease of -9.36%. This brings the company's revenue in the last twelve months to 8.60M, up 45.04% year-over-year. In the year 2023, Relief Therapeutics Holding had annual revenue of 6.03M, down -0.79%.
Revenue (ttm)
8.60M CHF
Revenue Growth
+45.04%
P/S Ratio
n/a
Revenue / Employee
175.47K CHF
Employees
49
Market Cap
35.52M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Relief Therapeutics Holding News
- 12 days ago - Relief Therapeutics to get European patent for investigational drug RLF‑TD011 - Seeking Alpha
- 12 days ago - Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011 - Accesswire
- 4 weeks ago - Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US - Accesswire
- 2 months ago - Relief Therapeutics advances merger talks with Renexxion - Seeking Alpha
- 2 months ago - Relief Therapeutics Provides Update on Potential Transaction with Renexxion - Accesswire
- 2 months ago - Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial - Accesswire
- 2 months ago - Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations - Accesswire
- 3 months ago - Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa - Accesswire